The European Union and the United States published the Guiding Principles for Good AI Practices in Drug Development on January 14, 2026, as part of a strategic effort to harmonize regulatory criteria. The EMA-FDA collaborative work initiative has the mission of promoting safety and accountability in the use of Artificial Intelligence with the aim of leveraging data, digitalization, and AI. This work has been analyzed and disseminated by por Guillem López, CSV & QA Manager at OYTEC, author of the article "The 10 Principles of Pharmaceutical AI according to the EMA and FDA". Common...